The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Traversa Sergio since 2015.
This trader's CIK number is 1565832.
At the time of last reporting, Traversa Sergio was the Chief Executive Officer of Relmada Therapeutics, Inc.. (stock ticker symbol RLMD).
Also see all insider trading activities at Relmada Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RLMD | 615,976 | $352,895 | 0 | $0 | 0 | $0 |
| 2024 | RLMD | 240,000 | $781,855 | 0 | $0 | 0 | $0 |
| 2022 | RLMD | 55,250 | $115,804 | 29,767 | $560,595 | 29,767 | $476,272 |
| 2021 | RLMD | 0 | $0 | 50,000 | $1,734,655 | 63,281 | $205,028 |
| 2020 | RLMD | 0 | $0 | 0 | $0 | 50,008 | $162,025 |
| 2015 | RLMD | 19,000 | $59,844 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2016 | ATNM | 3,000 | $6,060 | 0 | $0 | 0 | $0 |
1. Relmada Therapeutics, Inc. (RLMD)
2. Actinium Pharmaceuticals, Inc. (ATNM)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-26 | RLMD | Buy | 80,545 | .62 | 49,937 |
| 2025-08-27 | RLMD | Buy | 129,455 | .67 | 86,734 |
| 2025-08-28 | RLMD | Buy | 55,976 | .74 | 41,422 |
| 2025-05-16 | RLMD | Buy | 172,314 | .45 | 77,541 |
| 2025-05-20 | RLMD | Buy | 147,686 | .56 | 82,261 |
| 2025-05-19 | RLMD | Buy | 30,000 | .50 | 15,000 |
| 2024-09-09 | RLMD | Buy | 55,579 | 2.71 | 150,619 |
| 2024-09-10 | RLMD | Buy | 33,014 | 2.75 | 90,788 |
| 2024-09-11 | RLMD | Buy | 51,407 | 2.99 | 153,706 |
| 2024-01-31 | RLMD | Buy | 27,460 | 4.00 | 109,757 |
| 2024-01-30 | RLMD | Buy | 40,999 | 3.90 | 159,937 |
| 2024-01-29 | RLMD | Buy | 31,541 | 3.71 | 117,048 |
| 2022-12-08 | RLMD | Buy | 55,250 | 2.10 | 115,804 |
| 2022-06-30 | RLMD | Option Ex | 16,012 | 16.00 | 256,192 |
| 2022-07-01 | RLMD | Option Ex | 13,755 | 16.00 | 220,080 |
| 2022-06-30 | RLMD | Sale | 16,012 | 19.19 | 307,270 |
| 2022-07-01 | RLMD | Sale | 13,755 | 18.42 | 253,325 |
| 2021-03-09 | RLMD | Option Ex | 10,000 | 3.24 | 32,400 |
| 2021-03-09 | RLMD | Sale | 7,017 | 35.87 | 251,706 |
| 2021-03-10 | RLMD | Sale | 2,983 | 35.09 | 104,676 |
| 2021-02-24 | RLMD | Option Ex | 10,000 | 3.24 | 32,400 |
| 2021-02-24 | RLMD | Sale | 10,000 | 34.65 | 346,470 |
| 2021-02-11 | RLMD | Option Ex | 1,446 | 3.24 | 4,685 |
| 2021-02-11 | RLMD | Sale | 1,446 | 35.44 | 51,239 |
| 2021-02-10 | RLMD | Sale | 1,930 | 35.28 | 68,098 |
| 2021-02-09 | RLMD | Sale | 5,963 | 35.21 | 209,939 |
| 2021-02-08 | RLMD | Sale | 3,313 | 35.03 | 116,047 |
| 2021-02-08 | RLMD | Option Ex | 11,206 | 3.24 | 36,307 |
| 2021-02-03 | RLMD | Sale | 100 | 35.00 | 3,500 |
| 2021-02-02 | RLMD | Option Ex | 3,278 | 3.24 | 10,620 |
| 2021-02-02 | RLMD | Sale | 3,178 | 35.08 | 111,468 |
| 2021-02-02 | RLMD | Option Ex | 13,281 | 3.24 | 43,030 |
| 2021-01-27 | RLMD | Sale | 10,000 | 32.69 | 326,870 |
| 2021-01-27 | RLMD | Option Ex | 10,000 | 3.24 | 32,400 |
| 2021-01-22 | RLMD | Option Ex | 4,070 | 3.24 | 13,186 |
| 2021-01-22 | RLMD | Sale | 2,170 | 35.80 | 77,675 |
| 2021-01-25 | RLMD | Sale | 1,300 | 35.29 | 45,877 |
| 2021-01-26 | RLMD | Sale | 600 | 35.15 | 21,090 |
| 2020-08-18 | RLMD | Option Ex | 50,008 | 3.24 | 162,025 |
| 2015-12-15 | RLMD | Buy | 18,970 | 3.15 | 59,755 |
| 2015-12-14 | RLMD | Buy | 30 | 2.97 | 89 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-04-14 | ATNM | Buy | 2,000 | 2.02 | 4,040 |
| 2016-04-15 | ATNM | Buy | 1,000 | 2.02 | 2,020 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Traversa Sergio (Chief Executive Officer of Relmada Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.